PRRT – The Sequel? Alpha-emitter PRRT for Neuroendocrine Tumours (NET)
Updated and reviewed October 2026. Alpha‑emitter PRRT is emerging as the next major evolution of peptide receptor radionuclide therapy (and there is more to follow that!). What is Alpha-emitter? Instead of using a beta‑emitting isotope such as 177Lu, these new approaches use alpha‑particle–emitting isotopes like 212Pb or 225Ac. The goal is to deliver more powerful DNA‑damaging radiation directly into tumour cells while keeping the impact on surrounding tissues as low as possible. It's still experimental, but early clinical signals are strong enough that alpha‑emitter PRRT may now considered one of the most important areas to watch in NET research. In October…
